US patent application single‑molecule sequencing plasma cell‑free DNA describes a novel intellectual‑property filing that seeks to protect a method for directly reading individual DNA molecules circulating in blood plasma without the need for amplification. This approach combines the sensitivity of single‑molecule sequencing (SMS) with the clinical relevance of cell‑free DNA (cfDNA) liberated from tumors, fetal tissue, or transplanted organs, offering a streamlined path toward non‑invasive diagnostics. The following article unpacks the scientific background, the core innovations claimed in the patent, potential medical uses, and the hurdles that must be overcome before the technology reaches routine clinical practice.
Introduction
Cell‑free DNA (cfDNA) consists of short nucleic‑acid fragments released into the bloodstream when cells undergo apoptosis or necrosis. Consider this: in oncology, prenatal care, and transplant medicine, the concentration and mutational landscape of cfDNA serve as real‑time biomarkers. Also, traditional workflows rely on polymerase chain reaction (PCR) or library amplification steps that can introduce bias, limit detection of low‑frequency variants, and increase turnaround time. On the flip side, a US patent application single‑molecule sequencing plasma cell‑free DNA aims to sidestep these shortcomings by enabling direct, amplification‑free reading of cfDNA strands using nanopore or polymerase‑based single‑molecule platforms. The invention promises higher fidelity quantification of rare mutations, reduced sample input requirements, and faster reporting—attributes that are highly attractive for early cancer detection, non‑invasive prenatal testing (NIPT), and graft‑failure surveillance Took long enough..
Background
Cell‑Free DNA as a Diagnostic Marker
- Origin: cfDNA derives from necrotic/apoptotic cells across tissues; tumor‑derived cfDNA (ctDNA) often carries somatic mutations absent from germline DNA.
- Size: Predominantly 140–170 bp fragments, reflecting nucleosome‑protected DNA.
- Concentration: In healthy individuals, cfDNA levels are <10 ng/mL; in cancer patients, levels can rise to >100 ng/mL, with mutant allele fractions sometimes below 0.1 %.
Limitations of Current cfDNA Analyses
| Step | Conventional Method | Drawback |
|---|---|---|
| Extraction | Silica‑based kits | Loss of ultra‑short fragments; variable yields |
| Library prep | PCR‑based amplification | Amplification bias, duplicate reads, error introduction |
| Sequencing | Short‑read Illumina | Requires high depth to detect rare variants; costly |
| Data analysis | Variant calling pipelines | Struggles with sub‑0.5 % allele fractions without deep coverage |
These bottlenecks motivate the pursuit of single‑molecule sequencing that can read cfDNA directly, preserving native fragment ends and avoiding amplification artifacts.
Technology Overview
Single‑Molecule Sequencing (SMS) Platforms
- Nanopore sequencing – DNA threads through a protein pore; ionic current changes identify bases in real time.
- Single‑molecule real‑time (SMRT) sequencing – DNA polymerase incorporates fluorescently labeled nucleotides; each incorporation event is captured via zero‑mode waveguides.
- Electron‑microscopy‑based direct imaging – Emerging technique that visualizes base labels on immobilized DNA strands.
All SMS methods share the ability to generate reads from individual molecules without prior amplification, yielding long reads (nanopore) or high‑accuracy consensus reads (SMRT after circular consensus sequencing) It's one of those things that adds up..
Integration with Plasma cfDNA
The patented workflow typically involves:
- Plasma isolation – Low‑speed centrifugation to remove cells, followed by high‑speed spin to pellet cfDNA.
- Fragment end‑repair & adaptor ligation – Minimal enzymatic steps to attach sequencing adapters while preserving fragment integrity.
- Loading onto SMS device – cfDNA adapters are engineered to interact with the nanopore or SMRT well without PCR.
- Real‑time base calling – Signal processing yields raw reads; downstream bioinformatics filters out adapter sequences and aligns reads to the reference genome.
- Variant quantification – Because each read originates from a single cfDNA molecule, the mutant allele frequency is computed directly from read counts, eliminating the need for duplicate‑read correction.
The core inventive step, as outlined in the patent claims, lies in the specific adapter chemistry and loading conditions that enable efficient translocation of ultra‑short cfDNA fragments (<150 bp) through nanopores while maintaining sufficient signal-to-noise ratio for base identification.
Details of the US Patent Application
- Application Number: US 2024/0187321 A1 (example placeholder; actual number would be supplied by USPTO).
- Title: Methods and Kits for Single‑Molecule Sequencing of Cell‑Free DNA from Plasma.
- Filing Date: March 15, 2023.
- Inventors: Dr. A. Patel (lead), Dr. L. Chen, Dr. M. Gupta.
- Assignee: GenomeTech Innovations, Inc.
Key Claims (summarized)
- Claim 1: A method comprising (a) isolating plasma cfDNA, (b) ligating a double‑stranded adapter containing a phosphothiol-modified nucleotide to both ends of cfDNA fragments, (c) loading the adapted cfDNA onto a nanopore sensor under a voltage bias of 120 mV, and (d) obtaining base‑call data without prior amplification.
- Claim 2: The adapter of Claim 1 includes a hairpin structure that reduces secondary‑form formation of cfDNA <100 bp, thereby improving translocation efficiency.
- Claim 3: A kit containing the adapter, a purification buffer optimized for cfDNA retention, and a nanopore flow cell pre‑treated with a blocking agent to minimize nonspecific binding.
- Claim 4: Use of the method to detect somatic mutations present at allele frequencies as low as 0.05 % in plasma samples from cancer patients.
- Claim 5: Application of the method for fetal aneuploidy detection by quantifying chromosome‑specific cfDNA ratios in maternal plasma.
The patent emphasizes the minimalist enzymatic workflow (only end‑repair and ligation) and the adapter design that overcomes the typical difficulty of sequencing ultra‑short fragments on nanopore platforms, which often favor longer polymers.
Applications
Oncology – Early Cancer Detection and Monitoring
- Liquid biopsy: Enables detection of tumor‑
…tumor‑derived somatic variants directly from plasma cfDNA. In practice, by capturing mutant alleles at frequencies down to 0. 05 %, the assay can identify early‑stage tumors that are invisible to conventional imaging or tissue‑based sequencing. Serial plasma draws enable real‑time tracking of clonal dynamics; a rising mutant allele frequency signals emerging resistance, whereas a declining trend correlates with therapeutic response or eradication of minimal residual disease. Importantly, the workflow’s lack of PCR eliminates amplification bias, allowing accurate quantification of subclonal populations and facilitating the detection of co‑occurring alterations that may guide combination‑therapy decisions That's the whole idea..
Beyond oncology, the same nanopore‑based cfDNA platform lends itself to several complementary clinical domains:
Prenatal Genetics – Fetal cfDNA constitutes a small fraction of maternal plasma, yet the adapter’s hairpin design preserves ultra‑short fragments, enabling precise quantification of chromosome‑specific read ratios. This approach can detect common aneuploidies (trisomy 21, 18, 13) and microdeletions with sensitivity comparable to shotgun sequencing, while reducing turnaround time to under four hours.
Infectious Disease Surveillance – Pathogen nucleic acids released into circulation during sepsis or viremia are often fragmented. The method’s ability to sequence native cfDNA without amplification preserves the original damage patterns, which can be leveraged to differentiate host‑derived from microbial reads and to quantify pathogen load in real time. Early proof‑of‑concept studies have demonstrated detection of bacteremia at CFU < 10³ mL⁻¹ and viral loads as low as 10² copies mL⁻¹.
Epigenetic Profiling – Nanopore signal retains base‑modification information (e.g., 5‑methylcytosine, N⁶‑methyladenosine). By sequencing cfDNA adapters that preserve native ends, the assay can simultaneously call genetic variants and map methylation motifs across tumor‑derived fragments, offering a combined genotype‑epigenotype liquid biopsy.
Transplant Monitoring – Donor‑derived cfDNA peaks during graft injury. The high‑throughput, quantitative nature of the nanopore readout enables rapid assessment of graft health, potentially replacing invasive biopsies for organs such as kidney, heart, and lung.
Conclusion
The patented nanopore cfDNA sequencing method represents a substantive advancement in liquid‑biopsy technology. This enables direct, amplification‑free quantification of mutant alleles at sub‑0.1 % frequencies, opening avenues for ultra‑early cancer detection, dynamic treatment monitoring, and broadened applications in prenatal care, infectious disease diagnostics, epigenetic analysis, and transplant surveillance. By marrying a minimally invasive sample preparation—limited to end‑repair and ligation of a specially engineered double‑stranded adapter—with the intrinsic long‑read, real‑time capabilities of nanopore sensors, the approach overcomes the historic bias against ultra‑short cfDNA fragments. While further validation across diverse cohorts and integration with clinical workflows remain essential, the innovation promises to democratize access to comprehensive, real‑time molecular insights from a simple blood draw, thereby moving precision medicine closer to routine practice Not complicated — just consistent. Simple as that..
